OncoMethylome Sciences

OncoMethylome Sciences (EBR:ONCOB) Liège, Belgium - November 12, 2008, 08.00 CET - OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) announced today that it has signed a world-wide, non-exclusive license agreement with QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA). Under this agreement, QIAGEN has licensed certain of OncoMethylome's methylation technologies for use in certain of QIAGEN's future products. These products will expand, among others, QIAGEN's EpiTect product line. The agreement specifically covers the use of OncoMethylome's patented Methylation-Specific PCR (MSP) technology, the most widely applied epigenetic technology, for the scientific research market. Under the terms of the agreement, QIAGEN will pay OncoMethylome an upfront fee plus royalties from future sales of products utilizing this technology. Other terms of the agreement were not disclosed.

OncoMethylome Sciences (EBR:ONCOB) Liege (Belgium) - November 6, 2008, 08.00 CET - OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA), an innovative molecular diagnostics company, today issued its Q3 2008 business update, providing an overview of its financial position and summarizing material events that took place during this period.

OncoMethylome Sciences (EBR:ONCOB) LabCorp presents positive results on GST-Pi/APC methylation test for detection of prostate cancer OncoMethylome's methylation technology for improving the detection of prostate cancer was validated in a study presented by LabCorp.

OncoMethylome Sciences (EBR:ONCOB) Liege (Belgium) - Regulatory Release - September 12, 2008, 8:00 CET - OncoMethylome Sciences SA (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) publishes required information in accordance with new transparency legislation (Belgian Act of May 2, 2007) on disclosure of major holdings in issuers whose shares are admitted to trading on a regulated Belgian market.

OncoMethylome Sciences (EBR:ONCOB) First Methylation Tests are Launched and Available to Cancer Patients

OncoMethylome Sciences OncoMethylome's methylation detection technology is used in the new ColoSureTM colorectal cancer screening assay

OncoMethylome Sciences Liege (Belgium) - June 23, 2008, 08:00 CET - OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) announced today that it entered into a supply agreement with Laboratory Corporation of America® Holdings (LabCorp®). OncoMethylome agreed to sell reagents to LabCorp for detecting methylation of the Vimentin DNA marker with Methylation-Specific PCR (MSP). LabCorp plans to initially use the reagents for laboratory-developed, stool-based testing in North America that would serve as an option for traditionally non-compliant patients recommended for colorectal cancer screening. Under terms of the agreement, OncoMethylome will earn revenue for supplying the reagents and will also qualify for milestones tied to commercial use of the reagents by LabCorp.

OncoMethylome Sciences OncoMethylome's Technology to Be Used in Merck's Clinical Trial Program with Cilengitide

OncoMethylome Sciences Liege (Belgium) - May 29, 2008, 08:00 CET - OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) released additional data today from an ongoing clinical verification trial of their bladder cancer test.